Labeling changes implemented for spasticity drug

May 7, 2007

The FDA and manufacturer Acorda Therapeutics have made changes to the Contraindications and Warnings sections of the prescribing information for tizanidine (Zanaflex), regarding coadministration with CYP1A2 inhibitors.

The FDA and manufacturer Acorda Therapeutics have made changes to the Contraindications and Warnings sections of the prescribing information for tizanidine (Zanaflex), regarding coadministration with CYP1A2 inhibitors. Pharmacokinetic study results have shown that the serum concentration of tizanidine was significantly increased when it was taken with either fluvoxamine or ciprofloxacin. According to Acorda, although there are no additional data evaluating the effects of other CYP1A2 inhibitors on tizanidine, coadministration should be avoided.

 

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.